Wish to keep on prime of the science and politics driving biotech at the moment? Join to get our biotech publication in your inbox.
Hiya! Right now, we get some optimism from the brand new director of the Nationwide Most cancers Institute, regardless of a mind drain taking part in out within the business and stagnant funding numbers. Additionally, advocates press the federal authorities to encourage manufacturing for the prostate most cancers drug Xtandi.
Advocates press authorities to train march-in rights for Xtandi
Advocates are urgent the Biden administration to license patents for Xtandi, a prostate most cancers therapy, to different producers in order that lower-cost variations grow to be accessible. In a letter to CMS, they mentioned that two completely different federal legal guidelines — together with march-in rights — would permit the U.S. authorities to authorize “certified corporations” to make and promote generic variations of the blockbuster drug.
Xtandi, which is bought within the U.S. by Astellas and Pfizer, is at the moment priced three to 6 occasions increased than it’s in different high-income international locations. In 2022, the common Medicare worth was $130.66 per capsule; final yr, that rose to $136.50. In line with the CMS letter, the federal government payers spent greater than $5 billion on this U.S. government-funded most cancers drug.
The Biden administration rejected this petition a yr in the past, however since has issued a framework to say march-in rights to decrease prices of medicine created partially because of taxpayer {dollars}.
Learn extra.
NCI director optimistic about analysis regardless of logistical hurdles
The director of the Nationwide Most cancers Institute channeled Taylor Swift when talking this week on the American Affiliation for Most cancers Analysis — talking with optimism in regards to the previous, current, and future “eras” of most cancers analysis. Kimryn Rathmell famous that scientists are usually shifting from extra siloed analysis models to broader interdisciplinary groups, and that this can be a pattern that should proceed.
“I’m very optimistic,” she mentioned. “The sorts of questions that we will ask at the moment are simply unparalleled. I feel that the best way individuals are keen to work collectively and throughout boundaries has by no means been this sturdy or dedicated.”
That mentioned, she acknowledged that authorities funding for analysis scientists is stagnant or shrinking, saying that the company is contemplating chopping contractor bills and total personnel. That is exacerbating the continuing exodus of life scientists from academia.
“It’s very worrisome,” Rathmell mentioned. “We completely want primary discovery science… we want people who find themselves obsessed with that to maneuver into these fields and really feel like that discipline is a profession path for them.”
Learn extra.
The rationale for a 486% drug worth hike
An injectable eye drugs known as Triesence has been largely out of inventory for years, regardless of getting used to deal with a number of illnesses. Early final yr, a small firm known as Harrow purchased the therapy, and has plans to revamp and improve manufacturing of the drug — and enhance the worth by 486%. The drug was underpriced, and is “extraordinarily difficult” and “difficult” to fabricate, CEO Mark Baum instructed STAT. It took “tens of tens of millions of {dollars}” in manufacturing and regulatory prices in an effort to create a gentle new provide of the drugs.
“It’s a vital product in ophthalmology and proper now, if you happen to’re a retina surgeon or common ophthalmologist, you don’t have entry to it. The drug has not been accessible for 5 years,” Baum mentioned. “So whether or not it’s $160 or $944, it doesn’t matter. There’s no stock at any distributor.… Some vital investments need to be made. It was a Mannequin T car in a Tesla Mannequin S world.”
Learn extra.
Biotech financing at its highest in two years
After a three-year stoop, biotech startups simply had a superb fundraising quarter — elevating $6.8 million in enterprise financing. That’s essentially the most since early 2022, in keeping with knowledge from HSBC. This isn’t precisely sufficient to say the biotech sector has absolutely bounced again, an HSBC managing director instructed STAT.
“It’s actually laborious to speak about this with out saying it’s like the story of two cities, the place you see loads of actually fascinating momentum that’s very optimistic, however alternatively, you continue to have the frothiness of 2020 and 2021, within the type of increased valuations and perhaps corporations that, in a downturn, wouldn’t have gotten the funding that they did, having to work their method via that subsequent [investment] spherical,” he mentioned. “That’s nonetheless occurring, and that’s going to occur all through this yr and into early subsequent yr.”
Learn extra.
AskBio CSO steps down, has new venture in stealth mode
Jude Samulski, the early gene remedy pioneer, stepped down yesterday from his place as chief scientist of AskBio, the corporate he based in 2001 to commercialize his work at a time when pharma and buyers have been fleeing the sphere. He will probably be changed by Mansuo Shannon, who was chief scientist of the Eli Lilly subsidiary Prevail Therapeutics.
It’s a notable departure, coming 4 years after Bayer purchased AskBio and its pipeline of experimental therapies for as much as $4 billion. On the time, Samulski mentioned the corporate selected Bayer from a collection of suitors as a result of the German pharma promised to maintain its new subsidiary at arm’s size, leaving Samulski and then-CEO and co-founder Sheila Mikhail in cost. Now, Mikhail and Sumalski are gone (Mikhail left after a most cancers analysis). Outstanding gene remedy researcher Kathy Excessive additionally left final yr, after becoming a member of in 2021.
Samulski, who will keep on AskBio’s board, mentioned he isn’t performed. “Retirement, I don’t suppose so. Beginning one thing new in stealth mode,” he mentioned in a textual content message, including “You may publish that.”
Extra reads
- MassMutual is rolling out free genetic testing for members, a dicey space for all times insurers, STAT
- Virginia governor vetoes plan to create a prescription drug affordability board, STAT
- Novartis to cut back growth workforce by almost 700 positions, Endpoints